Journey Medical (DERM) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $13.1 million, consistent with Q1 2024, with Emrosi's U.S. launch contributing $2.1 million and offsetting Accutane declines due to increased competition.

• Emrosi, a new oral rosacea treatment, launched commercially in late March 2025, received FDA approval in November 2024, and is gaining strong prescriber visibility.

• Net loss narrowed to $4.1 million ($0.18/share) from $10.4 million ($0.53/share) in Q1 2024, reflecting reduced R&D expenses and improved operating leverage.

• Gross margin improved to 64% from 54% year-over-year, driven by product mix, lower product costs, and absence of prior year non-recurring charges.

• Cash position increased to $21.1 million as of March 31, 2025, up from $20.3 million at year-end 2024.

Financial highlights

• Product revenue: $13.1 million in Q1 2025 vs. $13.0 million in Q1 2024, with Emrosi contributing $2.1 million.

• Gross margin: 64% in Q1 2025, up from 54% in Q1 2024.

• Net loss: $4.1 million in Q1 2025 vs. $10.4 million in Q1 2024.

• SG&A expenses rose to $10.6 million from $8.4 million, reflecting investments in commercial infrastructure for Emrosi.

• Cash and cash equivalents: $21.1 million at March 31, 2025, up from $20.3 million at December 31, 2024.

Outlook and guidance

• Management expects Emrosi to drive sustainable EBITDA positivity and profitability later in 2025.

• Focus remains on expanding payer access, growing prescription volume, and publishing additional clinical data.

• No specific Q2 revenue guidance provided, but management anticipates continued revenue growth as demand pulls through distribution.

• Management is evaluating financing alternatives, including debt, equity, and out-licensing, to support operations and strategic initiatives.

• Substantial doubt exists about the company's ability to continue as a going concern for at least twelve months due to recurring losses.